These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34952247)

  • 1. Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh.
    Al-Emran HM; Hasan MS; Ahasan Setu MA; Rahman MS; Alam ARU; Sarkar SL; Islam MT; Islam MR; Rahman MM; Islam OK; Jahid IK; Hossain MA
    J Infect Public Health; 2022 Feb; 15(2):156-163. PubMed ID: 34952247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic characterization of the dominating Beta, V2 variant carrying vaccinated (Oxford-AstraZeneca) and nonvaccinated COVID-19 patient samples in Bangladesh: A metagenomics and whole-genome approach.
    Rahaman MM; Sarkar MMH; Rahman MS; Islam MR; Islam I; Saha O; Akter S; Banu TA; Jahan I; Habib MA; Goswami B; Bari L; Malek MA; Khan MS
    J Med Virol; 2022 Apr; 94(4):1670-1688. PubMed ID: 34939673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
    Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
    EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
    PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Oxford-AstraZeneca (ChAdOx1 CoV-19) vaccine against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) cases, hospital admissions, type of variants, and deaths.
    Meo SA; Aftab S; Bayoumy NM; Meo AS
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10133-10143. PubMed ID: 37916383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypothesis: Possible influence of antivector immunity and SARS-CoV-2 variants on efficacy of ChAdOx1 nCoV-19 vaccine.
    Zamai L; Rocchi MBL
    Br J Pharmacol; 2022 Jan; 179(2):218-226. PubMed ID: 34331459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
    Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N
    Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai.
    Shetty A; Chatterjee G; Rajpal S; Srivastava T; Gardi N; Mirgh S; Gokarn A; Punatar S; Shetty N; Joshi A; Nair S; Murthy V; Khattry N; Tembhare P; Dikshit R; Chaturvedi P; More A; Kamtalwar S; Chavan P; Bhat V; Patil A; Dhumal S; Bhat P; Subramanian P; Gujral S; Badwe R; Patkar N; Gupta S
    Int J Clin Pract; 2022; 2022():2449068. PubMed ID: 35685574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
    Clemens SAC; Folegatti PM; Emary KRW; Weckx LY; Ratcliff J; Bibi S; De Almeida Mendes AV; Milan EP; Pittella A; Schwarzbold AV; Sprinz E; Aley PK; Bonsall D; Fraser C; Fuskova M; Gilbert SC; Jenkin D; Kelly S; Kerridge S; Lambe T; Marchevsky NG; Mujadidi YF; Plested E; Ramasamy MN; Simmonds P; Golubchik T; Voysey M; Pollard AJ; ;
    Nat Commun; 2021 Oct; 12(1):5861. PubMed ID: 34615860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Koen AL; Izu A; Baillie V; Kwatra G; Cutland CL; Fairlie L; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Ahmed K; Bhikha S; Bhiman JN; du Plessis J; Esmail A; Horne E; Hwa SH; Oommen-Jose A; Lambe T; Laubscher M; Malahleha M; Benade G; McKenzie S; Oelofse S; Patel F; Pillay S; Rhead S; Rodel H; Taoushanis C; Tegally H; Thombrayil A; Villafana TL; Gilbert S; Pollard AJ; Madhi SA
    Vaccine; 2023 May; 41(23):3486-3492. PubMed ID: 37149443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
    Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
    Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variants of concern responsible for SARS-CoV-2 vaccine breakthrough infections from India.
    Singh UB; Rophina M; Chaudhry R; Senthivel V; Bala K; Bhoyar RC; Jolly B; Jamshed N; Imran M; Gupta R; Aggarwal P; Divakar MK; Sinha S; Arvinden VR; Bajaj A; Shamnath A; Jain A; ; Scaria V; Sivasubbu S; Guleria R
    J Med Virol; 2022 Apr; 94(4):1696-1700. PubMed ID: 34786733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sinopharm's BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2.
    Abdelhafiz AS; Ali A; Kamel MM; Ahmed EH; Sayed DM; Bakry RM
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of COVID-19 Breakthrough Infections and Severity in ChAdOx1 nCoV-19-Vaccinated Priority Groups.
    Kaur U; Bala S; Ojha B; Pathak BK; Joshi A; Yadav AK; Singh A; Kansal S; Chakrabarti SS
    Am J Trop Med Hyg; 2022 Oct; 107(4):850-855. PubMed ID: 35940202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.
    Paris C; Perrin S; Hamonic S; Bourget B; Roué C; Brassard O; Tadié E; Gicquel V; Bénézit F; Thibault V; Garlantézec R; Tattevin P
    Clin Microbiol Infect; 2021 Nov; 27(11):1699.e5-1699.e8. PubMed ID: 34265462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.